{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:50:57Z","timestamp":1775872257689,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,9]]},"DOI":"10.7759\/cureus.103323","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T06:55:35Z","timestamp":1770706535000},"source":"Crossref","is-referenced-by-count":1,"title":["Triple Infections With Campylobacter coli, Cytomegalovirus, and SARS-CoV-2 in a Lymphoma Patient Treated With Epcoritamab"],"prefix":"10.7759","author":[{"given":"Osamu","family":"Imataki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hina","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-00122-3","article-title":"The immuno-oncological challenge of COVID-19","volume":"1","author":"Derosa L","year":"2020","unstructured":"Derosa L, Melenotte C, Griscelli F, Gachot B, Marabelle A, Kroemer G, Zitvogel L. The immuno-oncological challenge of COVID-19. Nat Cancer. 2020, 1:946-64. 10.1038\/s43018-020-00122-3","journal-title":"Nat Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012251","article-title":"COVID-19 in patients with hematologic malignancy","volume":"140","author":"Langerbeins P","year":"2022","unstructured":"Langerbeins P, Hallek M. COVID-19 in patients with hematologic malignancy. Blood. 2022, 140:236-52. 10.1182\/blood.2021012251","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19","volume":"386","author":"Levin MJ","year":"2022","unstructured":"Levin MJ, Ustianowski A, De Wit S, et al.. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. N Engl J Med. 2022, 386:2188-200. 10.1056\/NEJMoa2116620","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05792-y","article-title":"Comprehensive procedure for injecting Evusheld\u00ae for hematological diseases in a single institute","volume":"103","author":"Imataki O","year":"2024","unstructured":"Imataki O, Yoshida S, Ishida T, Uemura M, Fujita H, Kadowaki N. Comprehensive procedure for injecting Evusheld\u00ae for hematological diseases in a single institute. Ann Hematol. 2024, 103:3193-8. 10.1007\/s00277-024-05792-y","journal-title":"Ann Hematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00203-025-04572-0","article-title":"Recent advances in infections as risk factors for lymphoma: a review of the effects of viral, bacterial, and fungal infections in lymphoma","volume":"208","author":"Xie T","year":"2025","unstructured":"Xie T, Shi C. Recent advances in infections as risk factors for lymphoma: a review of the effects of viral, bacterial, and fungal infections in lymphoma. Arch Microbiol. 2025, 208:5. 10.1007\/s00203-025-04572-0","journal-title":"Arch Microbiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab983","article-title":"Retrospective multicentric study on Campylobacter spp. bacteremia in France: the Campylobacteremia study","volume":"75","author":"Tin\u00e9vez C","year":"2022","unstructured":"Tin\u00e9vez C, Velardo F, Ranc AG, et al.. Retrospective multicentric study on Campylobacter spp. bacteremia in France: the Campylobacteremia study. Clin Infect Dis. 2022, 75:702-9. 10.1093\/cid\/ciab983","journal-title":"Clin Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08258-5","article-title":"Risk factors and clinical outcomes of cytomegalovirus diseases in hematologic malignancy patients without hematopoietic stem-cell transplantation","volume":"32","author":"Yang J","year":"2023","unstructured":"Yang J, Kang CI, Lee YH, et al.. Risk factors and clinical outcomes of cytomegalovirus diseases in hematologic malignancy patients without hematopoietic stem-cell transplantation. Support Care Cancer. 2023, 32:56. 10.1007\/s00520-023-08258-5","journal-title":"Support Care Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30251-9","article-title":"Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study","volume":"7","author":"Passamonti F","year":"2020","unstructured":"Passamonti F, Cattaneo C, Arcaini L, et al.. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020, 7:e737-45. 10.1016\/S2352-3026(20)30251-9","journal-title":"Lancet Haematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2031670","article-title":"Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer","volume":"383","author":"Aydillo T","year":"2020","unstructured":"Aydillo T, Gonzalez-Reiche AS, Aslam S, et al.. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020, 383:2586-8. 10.1056\/NEJMc2031670","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.48101\/ujms.v128.9807","article-title":"Persistent SARS-CoV-2 infection in patients with B-cell deficiency: a case series of successful antiviral treatment of four patients","volume":"128","author":"Fax\u00e9n L","year":"2023","unstructured":"Fax\u00e9n L, Edvinsson M. Persistent SARS-CoV-2 infection in patients with B-cell deficiency: a case series of successful antiviral treatment of four patients. Ups J Med Sci. 2023, 128:10.48101\/ujms.v128.9807","journal-title":"Ups J Med Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00031-X","article-title":"NICE guideline on long COVID","volume":"9","author":"Venkatesan P","year":"2021","unstructured":"Venkatesan P. NICE guideline on long COVID. Lancet Respir Med. 2021, 9:129. 10.1016\/S2213-2600(21)00031-X","journal-title":"Lancet Respir Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adh4529","article-title":"T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19","volume":"15","author":"Zonozi R","year":"2023","unstructured":"Zonozi R, Walters LC, Shulkin A, et al.. T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19. Sci Transl Med. 2023, 15:eadh4529. 10.1126\/scitranslmed.adh4529","journal-title":"Sci Transl Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.46","article-title":"Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors","volume":"10","author":"Kochenderfer JN","year":"2013","unstructured":"Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013, 10:267-76. 10.1038\/nrclinonc.2013.46","journal-title":"Nat Rev Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.187","article-title":"Novel immunotherapies in lymphoid malignancies","volume":"13","author":"Batlevi CL","year":"2016","unstructured":"Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol. 2016, 13:25-40. 10.1038\/nrclinonc.2015.187","journal-title":"Nat Rev Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015588555","article-title":"Blinatumomab: a first-in-class bispecific T-cell engager for precursor B-cell acute lymphoblastic leukemia","volume":"49","author":"Buie LW","year":"2015","unstructured":"Buie LW, Pecoraro JJ, Horvat TZ, Daley RJ. Blinatumomab: a first-in-class bispecific T-cell engager for precursor B-cell acute lymphoblastic leukemia. Ann Pharmacother. 2015, 49:1057-67. 10.1177\/1060028015588555","journal-title":"Ann Pharmacother"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01930-4","article-title":"Epcoritamab: first approval","volume":"83","author":"Frampton JE","year":"2023","unstructured":"Frampton JE. Epcoritamab: first approval. Drugs. 2023, 83:1331-40. 10.1007\/s40265-023-01930-4","journal-title":"Drugs"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont C","year":"2023","unstructured":"Thieblemont C, Phillips T, Ghesquieres H, et al.. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J Clin Oncol. 2023, 41:2238-47. 10.1200\/JCO.22.01725","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001792","article-title":"BiTEs better than CAR T cells","volume":"5","author":"Subklewe M","year":"2021","unstructured":"Subklewe M. BiTEs better than CAR T cells. Blood Adv. 2021, 5:607-12. 10.1182\/bloodadvances.2020001792","journal-title":"Blood Adv"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa451","article-title":"Duration of viral shedding of discharged patients with severe COVID-19","volume":"71","author":"Zhou B","year":"2020","unstructured":"Zhou B, She J, Wang Y, Ma X. Duration of viral shedding of discharged patients with severe COVID-19. Clin Infect Dis. 2020, 71:2240-2. 10.1093\/cid\/ciaa451","journal-title":"Clin Infect Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou F","year":"2020","unstructured":"Zhou F, Yu T, Du R, et al.. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020, 395:1054-62. 10.1016\/S0140-6736(20)30566-3","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-6-86","article-title":"Recurrent bacteremia with Helicobacter cinaedi: case report and review of the literature","volume":"6","author":"U\u00e7kay I","year":"2006","unstructured":"U\u00e7kay I, Garbino J, Dietrich PY, Ninet B, Rohner P, Jacomo V. Recurrent bacteremia with Helicobacter cinaedi: case report and review of the literature. BMC Infect Dis. 2006, 6:86. 10.1186\/1471-2334-6-86","journal-title":"BMC Infect Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3201\/eid2911.230598","article-title":"Campylobacter fetus invasive infections and risks for death, France, 2000-2021","volume":"29","author":"Zayet S","year":"2023","unstructured":"Zayet S, Klopfenstein T, Gendrin V, et al.. Campylobacter fetus invasive infections and risks for death, France, 2000-2021. Emerg Infect Dis. 2023, 29:2189-97. 10.3201\/eid2911.230598","journal-title":"Emerg Infect Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01447-23","article-title":"Antimicrobial susceptibilities of Campylobacter fetus: report from a reference laboratory","volume":"62","author":"Zhang MM","year":"2024","unstructured":"Zhang MM, Melton TA, Akhtar H, Shah A, Schuetz AN, Clement J, Stevens RW. Antimicrobial susceptibilities of Campylobacter fetus: report from a reference laboratory. J Clin Microbiol. 2024, 62:e0144723. 10.1128\/jcm.01447-23","journal-title":"J Clin Microbiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3400\/avd.cr.17-00135","article-title":"Infected abdominal aortic aneurysm caused by Campylobacter jejuni","volume":"11","author":"Yanase Y","year":"2018","unstructured":"Yanase Y, Ohkawa A, Inoue S, Niida Y. Infected abdominal aortic aneurysm caused by Campylobacter jejuni. Ann Vasc Dis. 2018, 11:239-42. 10.3400\/avd.cr.17-00135","journal-title":"Ann Vasc Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-020-05582-7","article-title":"Infected aortic aneurysm caused by Helicobacter cinaedi: case series and systematic review of the literature","volume":"20","author":"Matsuo T","year":"2020","unstructured":"Matsuo T, Mori N, Mizuno A, et al.. Infected aortic aneurysm caused by Helicobacter cinaedi: case series and systematic review of the literature. BMC Infect Dis. 2020, 20:854. 10.1186\/s12879-020-05582-7","journal-title":"BMC Infect Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf406","article-title":"Differences in the clinical characteristics of campylobacteriosis between immunocompromised and immunocompetent patients: a single-center retrospective cohort study in Japan","volume":"12","author":"Shinohara K","year":"2025","unstructured":"Shinohara K, Tsuda Y, Tsuchido Y, Yamamoto M, Matsumura Y, Nagao M. Differences in the clinical characteristics of campylobacteriosis between immunocompromised and immunocompetent patients: a single-center retrospective cohort study in Japan. Open Forum Infect Dis. 2025, 12:ofaf406. 10.1093\/ofid\/ofaf406","journal-title":"Open Forum Infect Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012916","article-title":"Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis","volume":"8","author":"Reynolds GK","year":"2024","unstructured":"Reynolds GK, Maclean M, Cliff ER, et al.. Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis. Blood Adv. 2024, 8:3555-9. 10.1182\/bloodadvances.2024012916","journal-title":"Blood Adv"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings M","year":"2021","unstructured":"Hutchings M, Mous R, Clausen MR, et al.. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study. Lancet. 2021, 398:1157-69. 10.1016\/S0140-6736(21)00889-8","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3667","article-title":"Dissecting the mechanisms underlying the cytokine release syndrome (CRS) mediated by T-cell bispecific antibodies","volume":"29","author":"Leclercq-Cohen G","year":"2023","unstructured":"Leclercq-Cohen G, Steinhoff N, Albert\u00ed Servera L, et al.. Dissecting the mechanisms underlying the cytokine release syndrome (CRS) mediated by T-cell bispecific antibodies. Clin Cancer Res. 2023, 29:4449-63. 10.1158\/1078-0432.CCR-22-3667","journal-title":"Clin Cancer Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types","volume":"126","author":"Einsele H","year":"2020","unstructured":"Einsele H, Borghaei H, Orlowski RZ, et al.. The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer. 2020, 126:3192-201. 10.1002\/cncr.32909","journal-title":"Cancer"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler ME","year":"2020","unstructured":"Goebeler ME, Bargou RC. T cell-engaging therapies - BiTEs and beyond. Nat Rev Clin Oncol. 2020, 17:418-34. 10.1038\/s41571-020-0347-5","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/436531-triple-infections-with-campylobacter-coli-cytomegalovirus-and-sars-cov-2-in-a-lymphoma-patient-treated-with-epcoritamab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T06:55:36Z","timestamp":1770706536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/436531-triple-infections-with-campylobacter-coli-cytomegalovirus-and-sars-cov-2-in-a-lymphoma-patient-treated-with-epcoritamab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.103323","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,9]]}}}